Ernexa Therapeutics Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
ERNA Nasdaq 2836 www.ernexatx.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Ernexa Therapeutics Inc.

Ernexa Therapeutics Announces Successful Pre-IND FDA Meeting and Continues Progress Toward First-in-Human Trial in Ovarian Cancer - Jan 6th, 2026 6:15 am
Ernexa Therapeutics Presents New Preclinical Data at American Society of Hematology (ASH) Annual Meeting on Lead Cell Therapy Candidate for Treatment of Ovarian Cancer - Dec 8th, 2025 6:30 am
Ernexa Therapeutics Announces Oral Presentation at the 67th American Society of Hematology (ASH) Annual Meeting - Dec 3rd, 2025 6:30 am
Ernexa Therapeutics Strengthens Scientific and Medical Advisory Board with Appointment of Leading Oncologist Dr. Ira S. Winer, M.D., Ph.D., FACOG - Dec 2nd, 2025 6:50 am
Ernexa Therapeutics to Present at Oxford Global’s Cell 2025 - Nov 11th, 2025 5:00 am
Ernexa Therapeutics Reports Strong Quarterly Performance, Highlighting Operational Execution and Progress Toward First-in-Human Cell Therapy Trials - Nov 10th, 2025 6:35 am
Ernexa Therapeutics Showcases Strategic Partnership with Cellipont Bioservices to Advance Toward First-in-Human Trials on Virtual Investor “What This Means” Platform - Nov 6th, 2025 7:15 am
/C O R R E C T I O N -- Cellipont Bioservices/ - Oct 29th, 2025 8:32 am
BC-Most Active Stocks - Oct 29th, 2025 8:30 am
Ernexa Therapeutics to Deliver Company Presentation at the Annual Cell & Gene Meeting on the Mesa - Oct 1st, 2025 6:30 am
Ernexa Therapeutics President & CEO Sanjeev Luther to Present on Expert Panel at 5th Annual iPSC Drug Development Summit - Sep 29th, 2025 6:30 am
Ernexa Therapeutics to Present New Data in Oral Presentation at AACR Special Conference in Cancer Research - Sep 17th, 2025 6:30 am
Ernexa Therapeutics Provides Update on Operational Excellence and Performance - Sep 10th, 2025 6:30 am
Ernexa Therapeutics Announces Presentation At The H.C. Wainwright 27th Annual Global Investment Conference - Sep 3rd, 2025 7:30 am
Ernexa Therapeutics First Half 2025 Earnings: US$2.91 loss per share (vs US$33.78 loss in 1H 2024) - Aug 15th, 2025 5:55 am
Ernexa Therapeutics Regains Compliance with Nasdaq Listing Requirements - Jul 9th, 2025 6:30 am
Ernexa Therapeutics Expands Advisory Board to Form Integrated Scientific and Medical Advisory Board as it Prepares for Clinical Development - Jun 25th, 2025 6:30 am
Ernexa Therapeutics Secures $6 Million in Second Closing Under Securities Purchase Agreement - Jun 24th, 2025 6:30 am
Ernexa Therapeutics announces 1-for-15 reverse stock split - Jun 11th, 2025 7:35 am
Ernexa Therapeutics Announces New Data to be Presented at ASCO Annual Meeting 2025 - May 28th, 2025 6:30 am